Camp4 Therapeutics获澳大利亚监管批准,启动Cmp-002在SYNGAP1相关障碍患者中的首次人体临床试验

美股速递
Jul 27

Camp4 Therapeutics公司已成功获得澳大利亚监管部门的批准,得以启动Cmp-002针对SYNGAP1相关障碍患者的首次人体临床试验。这一里程碑式的进展,标志着该公司在罕见遗传性神经系统疾病治疗领域迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10